ClinicalTrials.gg
Active, not recruitingNCT06993480Updated Aug 10, 2026

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

A Phase 2 interventional study of AHB-137 in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Enrollment
11th of 11
20 · median 86
Started
2025
with 3 others
Phase 2
7 of 11
5 open now
Registered
4th of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one is the 11th largest by enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 4th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Hepatitis B, Chronic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participated in the study and signed an form;
  • Aged between 18 and 55 years at the time of signing the informed consent form;
  • (BMI) within the range of 18-30 kg/ m2;
  • HBeAg negative or positive at screening;
  • or HBV DNA positive for at least 6 months;
  • Have been on continuous nucleos(t)ide analogues antiviral therapy for more than 6 months prior to screening;
  • 100 IU/mL \< HBsAg ≤ 3000 IU/mL and HBV DNA \< 100 IU/mL at screening;
  • (ALT) ≤ 2 × (ULN);
  • Effective as required.

Exclusion criteria

Exclusion Criteria:

  • abnormalities other than a history of CHB infection;
  • Concomitant clinically significant other liver diseases;
  • Any serious infection other than CHB infection requiring intravenous anti-infective therapy within 1 month prior to screening;
  • Active , (HIV) positive, syphilis positive;
  • Liver stiffness value (LSM) > 9.0 kPa at screening;
  • Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein (AFP) concentration ≥ 20 ng/mL at screening;
  • Participants with confirmed or suspected hepatic decompensated cirrhosis;
  • Liver at screening assessed severity of activity ≥ G3 grade and/or fibrosis reaching S4 stage;
  • History of extrahepatic disease possibly related to HBV immune status;
  • Ongoing or taking any medication within 3 months prior to screening. Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose, or have a history of vaccination within 1 month prior to screening or have a plan during the trial; Continuous use of traditional Chinese medicine for more than 2 months within 1 year prior to screening, or within 1 month prior to screening; Ongoing use of anticoagulants, bleeding tendency or coagulopathy, or conditions that, in the opinion of the investigator, increase the risk of liver biopsy;
  • Receiving or using any interferon-containing therapy within 12 months prior to screening;
  • History of within 5 years prior to screening or being evaluated for possible malignancy;
  • Suspected history of allergy to any component of the study drug, or allergic constitution (multiple drug and food allergy, and judged by the investigator to be clinically significant);
  • Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study;
  • Donation or blood loss ≥ 400 mL, or received blood transfusion within 12 weeks prior to screening; Or blood donation or blood loss ≥ 200 mL within 1 month prior to screening;
  • Participants who are participating in another clinical trial, or have not undergone a protocol-specified prior to this study;
  • Received any antisense oligonucleotides (ASO) or using any small molecule interfering ribonucleic acid (siRNA) drug within 12 months prior to screening;
  • Participants with abnormal thyroid function judged by the investigator to be ineligible for enrollment;
  • Obviously abnormal laboratory test results;
  • History of vasculitis or signs and symptoms of underlying vasculitis;
  • Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    AHB-137

    AHB-137 will be injected subcutaneously.

    Drug: AHB-137

Interventions

  • AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).

06

What researchers measure

Primary outcomes

  1. Proportion of participants with serum HBsAg < limit of detection (LOD) 0.05 international unit per milliliter (IU/mL) and Hepatitis B Virus (HBV) DNA < lower limit of quantification (LLOQ) with or without HBsAb seroconversion.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Number and percentage of participants with serum HBsAg < LOD and/or HBV DNA < LLOQ.

    Time frame: Up to 72 weeks

  2. Proportion of participants maintaining sustained response;

    Time frame: Up to 48 weeks

  3. The changes of liver HBsAg, HBcAg, HBV RNA, integration HBV DNA and covalently closed circular DNA (cccDNA) compared to baseline;

    Time frame: Up to 72 weeks

  4. The changes in the phenotype of liver immune cells compared to baseline;

    Time frame: Up to 72 weeks

  5. The changes of peripheral blood cytokines compared to baseline;

    Time frame: Up to 72 weeks

  6. The changes of peripheral blood immune cell phenotypes compared to baseline;

    Time frame: Up to 72 weeks

  7. The changes of serum HBsAg, HBsAb, HBV DNA, HBV RNA, HBeAg, HBeAb compared to baseline;

    Time frame: Up to 72 weeks

  8. The changes in peripheral blood metabolomics compared to baseline;

    Time frame: Up to 72 weeks

  9. The changes in peripheral blood proteomics compared to baseline;

    Time frame: Up to 72 weeks

  10. The changes in liver metabolomics compared to baseline, if applicable ;

    Time frame: Up to 72 weeks

  11. AHB-137 drug concentrations, and metabolite profiling, if applicable;

    Time frame: Up to 72 weeks

  12. Number and percentage of participants with detectable anti-drug antibodies (ADA);

    Time frame: Up to 72 weeks

  13. Safety: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.

    Examination including laboratory examination, electrocardiogram (ECG) examination.

    Time frame: Up to 72 weeks

  14. After discontinuation of all chronic hepatitis B treatments for 24 weeks, HBV DNA was below the limit of quantification (LLOQ), and HBsAg was below the detection limit (0.05 IU/mL), with HBeAg being negative, with or without the presence of HBsAg.

    Time frame: Up to 72 weeks.

  15. After discontinuation of all chronic hepatitis B treatments for 24 weeks, HBV DNA was below the limit of quantification (LLOQ), and HBsAg was less than 10 IU/mL.

    Time frame: Up to 72 weeks

  16. Whether the NA treatment discontinuation criteria have been met during the assessment of NA treatment discontinuation.

    Time frame: 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 24 months is close to that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 28, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Jul 27, 2027
CompletionEst.
Nov 27, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06993480
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Jul 15, 2025
Primary completion
Jul 27, 2027 (estimated)
Completion
Nov 27, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Dazhi Zhang
principal investigator · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion